Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487338 | 1.00 | MPO (0.41) | MPOACHEBACE1HTTCYP1A2 | |
| SCHEMBL3498669 | 0.84 | HTT (0.44) | MPOACHEHTTCYP1A2CYP2C19 | |
| SCHEMBL7427955 | 0.81 | MPO (0.46) | MPOACHEBACE1HTTCYP1A2 | |
| SCHEMBL5498929 | 0.81 | HRH4 (0.50) | MPOACHEBACE1HTTPABPC1 | |
| SCHEMBL15054414 | 0.77 | MPO (0.46) | MPOACHEERN1HRH4ALOX15 | |
| SCHEMBL3503833 | 0.77 | MPO (0.40) | MPOACHEBACE1HTTCYP1A2 | |
| SCHEMBL1692503 | 0.77 | MPO (0.40) | MPOACHEBACE1HTTCYP1A2 | |
| SCHEMBL17384456 | 0.77 | MPO (0.43) | MPOACHEBACE1HTTCYP1A2 | |
| SCHEMBL14283162 | 0.77 | ACHE (0.38) | MPOACHEBACE1HTTCYP1A2 | |
| SCHEMBL24777192 | 0.76 | MPO (0.41) | MPOACHEBACE1HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220185832-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-16 | — | — | US | disclosed |
| CN-114206841-A | CD73 inhibitor | 博奥阿迪斯生物科技公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020211668-A1 | CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020210938-A1 | QUINAZOLINE DERIVATIVES AS CD73 INHIBITORS | BIOARDIS LLC (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20100098788-A1 | Extracts of Curcuma and Methods of Use Thereof | HERBALSCIENCE GROUP, LLC | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185832-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | MPO 660/4885ACHE 1259/4885BACE1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.